David Dible

Director
Head of the Phama & Biotech team

David has over 25 years of experience in the healthcare, pharmaceutical and biotechnology sectors. In the last three and half years, David has worked on over ten European sector IPOs including Zentiva, TopoTarget, Arpida,ThromboGenics and Pharmstandard. He also provided broad ranging communications consultancy on high profile M&A transactions for companies such as Lonza and Zentiva. David has a clear understanding of conducting financial communications globally. He has been a rated pharma analyst in the UK, Europe and Japan. In addition to being a successful investment manager he has run cross-border investor relations and financial communications in-house for a number of international biotech and healthcare companies.

David has  a BSc In Biological Sciences from Edinburgh University.